Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/74158
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Díaz Chico, Nicolás | en_US |
dc.contributor.author | García Jordá, Enrique | en_US |
dc.date.accessioned | 2020-08-18T22:39:36Z | - |
dc.date.available | 2020-08-18T22:39:36Z | - |
dc.date.issued | 2008 | en_US |
dc.identifier.issn | 1699-048X | en_US |
dc.identifier.other | Scopus | - |
dc.identifier.uri | http://hdl.handle.net/10553/74158 | - |
dc.language | spa | en_US |
dc.relation.ispartof | Clinical and Translational Oncology | en_US |
dc.source | Clinical and Translational Oncology [ISSN 1699-048X], v. 10 (5), p. 248-249, (Diciembre 2008) | en_US |
dc.subject | 320101 Oncología | en_US |
dc.subject.other | Venture Capital | en_US |
dc.subject.other | Cancer Research Networking | en_US |
dc.subject.other | Spanish Association | en_US |
dc.subject.other | Cancer Research Group | en_US |
dc.subject.other | Funding Distribution | en_US |
dc.title | An interview with Nicolás Díaz Chico, president of the Spanish Association for Cancer Research (ASEICA) | en_US |
dc.type | info:eu-repo/semantics/Article | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1007/s12094-008-0192-y | en_US |
dc.identifier.scopus | 56149088796 | - |
dc.contributor.authorscopusid | 25723175700 | - |
dc.description.lastpage | 249 | en_US |
dc.identifier.issue | 5 | - |
dc.description.firstpage | 248 | en_US |
dc.relation.volume | 10 | en_US |
dc.investigacion | Ciencias de la Salud | en_US |
dc.type2 | Artículo | en_US |
dc.utils.revision | Sí | en_US |
dc.date.coverdate | Diciembre 2008 | en_US |
dc.identifier.ulpgc | Sí | es |
dc.description.scie | SCIE | |
item.grantfulltext | none | - |
item.fulltext | Sin texto completo | - |
Appears in Collections: | Artículos |
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.